Taken together, these data indicate that in untreated, poor outcome patients, a subset of CD30+ cells that express high levels of FGF2 and SDC1 transcripts, perhaps HRS cells, made their way into the circulation, and may be responsible for the poor outcome generated in primary refractory and early relapsing NS-cHL patients. The gene discussed is SDC1; the disease is classic Hodgkin lymphoma.